ATE333446T1 - Pyrimidin-4-onderivat als ldl-pla2 inhibitor - Google Patents

Pyrimidin-4-onderivat als ldl-pla2 inhibitor

Info

Publication number
ATE333446T1
ATE333446T1 AT01907522T AT01907522T ATE333446T1 AT E333446 T1 ATE333446 T1 AT E333446T1 AT 01907522 T AT01907522 T AT 01907522T AT 01907522 T AT01907522 T AT 01907522T AT E333446 T1 ATE333446 T1 AT E333446T1
Authority
AT
Austria
Prior art keywords
ldl
pyrimidine
derivative
pla2 inhibitor
pla2
Prior art date
Application number
AT01907522T
Other languages
English (en)
Inventor
Deirdre Mary B Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Steven James Stanway
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003636A external-priority patent/GB0003636D0/en
Priority claimed from GB0101437A external-priority patent/GB0101437D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE333446T1 publication Critical patent/ATE333446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01907522T 2000-02-16 2001-02-13 Pyrimidin-4-onderivat als ldl-pla2 inhibitor ATE333446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0003636A GB0003636D0 (en) 2000-02-16 2000-02-16 Novel compounds
GB0101437A GB0101437D0 (en) 2001-01-19 2001-01-19 Novel Compounds

Publications (1)

Publication Number Publication Date
ATE333446T1 true ATE333446T1 (de) 2006-08-15

Family

ID=26243663

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06075890T ATE437862T1 (de) 2000-02-16 2001-02-13 Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
AT01907522T ATE333446T1 (de) 2000-02-16 2001-02-13 Pyrimidin-4-onderivat als ldl-pla2 inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06075890T ATE437862T1 (de) 2000-02-16 2001-02-13 Pyrimidin-5-onderivate als ldl-pla2 inhibitoren

Country Status (32)

Country Link
US (10) US20020103213A1 (de)
EP (2) EP1263740B1 (de)
JP (1) JP4095804B2 (de)
KR (1) KR100781425B1 (de)
CN (1) CN1179952C (de)
AR (1) AR030190A1 (de)
AT (2) ATE437862T1 (de)
AU (2) AU3546601A (de)
BG (1) BG66014B1 (de)
BR (1) BRPI0108396B1 (de)
CA (1) CA2400554C (de)
CO (1) CO5271661A1 (de)
CY (2) CY1105649T1 (de)
CZ (1) CZ304450B6 (de)
DE (2) DE60139429D1 (de)
DK (2) DK1263740T3 (de)
ES (2) ES2330552T3 (de)
GC (1) GC0000221A (de)
HK (1) HK1053466A1 (de)
HU (1) HU229479B1 (de)
IL (2) IL151236A (de)
MX (1) MXPA02008062A (de)
MY (1) MY135732A (de)
NO (1) NO324691B1 (de)
NZ (1) NZ520752A (de)
PL (1) PL209824B1 (de)
PT (2) PT1686119E (de)
SI (2) SI1263740T1 (de)
SK (1) SK287296B6 (de)
TW (1) TW550259B (de)
UA (1) UA73762C2 (de)
WO (1) WO2001060805A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330552T3 (es) 2000-02-16 2009-12-11 Smithkline Beecham Plc Derivados de pirimidin-5-ona como inhibidores de ldl-pla2.
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
EP1326830A1 (de) * 2000-10-20 2003-07-16 Biovitrum Ab 2-,3-,4- oder 5-substituierte n1-(benzolsulfonyl)endole und deren verwendung in der therapie
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
WO2003057671A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Compose biaryle et son utilisation
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
JP4366122B2 (ja) * 2003-06-24 2009-11-18 日立オムロンターミナルソリューションズ株式会社 紙葉類搬送装置
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
CN1875002B (zh) 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP4906715B2 (ja) 2004-05-08 2012-03-28 ニューロジェン・コーポレーション ４，５−ジ置換−２−アリールピリミジン類
DE102004061005A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Cycloalkyl-1,2,4-triazin-5(2H)-one
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101563753B1 (ko) * 2007-05-11 2015-10-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 피부 궤양의 치료 방법
MX2009012188A (es) 2007-05-11 2010-02-24 Univ Jefferson Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
US8637524B2 (en) 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona
ES2611150T3 (es) 2010-06-18 2017-05-05 The Whitehead Institute For Biomedical Research PLA2G16 como diana para compuestos antivirales
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
WO2012076435A1 (en) 2010-12-06 2012-06-14 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
EP2649050A4 (de) * 2010-12-06 2014-04-23 Glaxo Group Ltd Verbindungen
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
CN102643269B (zh) * 2011-02-21 2014-07-23 天津药物研究院 一类含吡唑结构的磷脂酶a2抑制剂及用途
CN103476414B (zh) * 2011-03-16 2015-07-08 中国科学院上海药物研究所 季铵盐类化合物、其制备方法、药物组合物及用途
WO2012129792A1 (zh) * 2011-03-30 2012-10-04 中国科学院上海药物研究所 嘧啶酮类化合物、其制备方法及药物组合物和用途
WO2013000267A1 (zh) 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
CN103827116B (zh) * 2011-07-27 2016-08-31 葛兰素集团有限公司 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
BR112015017768A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos
RU2015135824A (ru) 2013-01-25 2017-03-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
EP2948452B1 (de) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Auf 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h-)-on basierende lipoprotein-assoziierte phospholipase-a2 (lp-pla2)-inhibitoren
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2015087239A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Processes for the preparation of darapladib and its intermediates
WO2015092687A2 (en) 2013-12-17 2015-06-25 Ranbaxy Laboratories Limited Process for the purification of darapladib
WO2015114479A1 (en) 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
US10464896B2 (en) * 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
BR112018012112A2 (pt) * 2015-12-16 2018-12-04 Bristol-Myers Squibb Company heteroaril-hidroxipirimidinonas como agonistas do receptor apj
US10878307B2 (en) * 2016-12-23 2020-12-29 Microsoft Technology Licensing, Llc EQ-digital conversation assistant
EP3687980B1 (de) 2017-09-26 2022-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Radioaktiv markiertes darapladib, analoga davon und deren verwendung als bildgebungsverbindungen
CN110746445B (zh) * 2019-10-16 2021-03-16 深圳海关食品检验检疫技术中心 一种头孢哌酮氘代内标物的制备方法
MX2022005615A (es) 2019-11-09 2022-07-27 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo.
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
EP4257133A1 (de) 2022-04-05 2023-10-11 Institut Pasteur Oxo-azaheterozyklische derivate zur verwendung bei der behandlung von malaria

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981252A (en) 1993-06-25 1999-11-09 Smithkline Beecham Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
DE69434609T2 (de) * 1993-10-06 2006-09-21 Icos Corp., Bothell Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
AU708032B2 (en) 1995-07-01 1999-07-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
CA2233300A1 (en) 1995-09-29 1997-04-10 Christopher Donald Southan A paf-acetylhydrolase and use in therapy
EP0865429A1 (de) 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinon-verbindungen zur behandlung von atherosklerose
WO1997021675A1 (en) 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
HUP9901359A3 (en) 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
US6417192B1 (en) * 1997-11-06 2002-07-09 Smithkline Beecham P.L.C. Pyrimidinone compounds and pharmaceutical compositions containing them
ATE251613T1 (de) 1998-08-21 2003-10-15 Smithkline Beecham Plc Pyrimidinonderivate zur behandlung von atheroscleros
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
DK1175408T3 (da) * 1999-05-01 2005-04-11 Smithkline Beecham Plc Pyrimidinonforbindelser
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
ES2330552T3 (es) 2000-02-16 2009-12-11 Smithkline Beecham Plc Derivados de pirimidin-5-ona como inhibidores de ldl-pla2.
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CY1109484T1 (el) 2014-08-13
US20020103213A1 (en) 2002-08-01
BG107034A (bg) 2003-04-30
HK1053466A1 (en) 2003-10-24
BRPI0108396B1 (pt) 2015-05-19
DK1263740T3 (da) 2006-11-13
DE60121550T2 (de) 2007-06-21
SI1263740T1 (sl) 2006-12-31
PL209824B1 (pl) 2011-10-31
CY1105649T1 (el) 2010-12-22
US20040097525A1 (en) 2004-05-20
ATE437862T1 (de) 2009-08-15
US7638520B2 (en) 2009-12-29
US6649619B1 (en) 2003-11-18
JP4095804B2 (ja) 2008-06-04
CZ20022768A3 (cs) 2003-05-14
AR030190A1 (es) 2003-08-13
US20150045375A1 (en) 2015-02-12
KR100781425B1 (ko) 2007-12-03
PT1686119E (pt) 2009-10-06
US20120172378A1 (en) 2012-07-05
US20090118313A1 (en) 2009-05-07
PL357382A1 (en) 2004-07-26
SI1686119T1 (sl) 2009-12-31
KR20030011772A (ko) 2003-02-11
NZ520752A (en) 2004-03-26
JP2003523335A (ja) 2003-08-05
WO2001060805A1 (en) 2001-08-23
US20090170877A1 (en) 2009-07-02
AU3546601A (en) 2001-08-27
IL181957A0 (en) 2009-02-11
US7153861B2 (en) 2006-12-26
NO20023828D0 (no) 2002-08-13
SK287296B6 (sk) 2010-06-07
EP1263740A1 (de) 2002-12-11
NO20023828L (no) 2002-09-30
DE60139429D1 (de) 2009-09-10
UA73762C2 (uk) 2005-09-15
BR0108396A (pt) 2003-03-11
CA2400554C (en) 2009-04-07
DE60121550D1 (de) 2006-08-31
HUP0204410A2 (en) 2003-05-28
NO324691B1 (no) 2007-12-03
EP1263740B1 (de) 2006-07-19
AU2001235466B2 (en) 2004-04-22
MY135732A (en) 2008-06-30
GC0000221A (en) 2006-03-29
US20070155762A1 (en) 2007-07-05
CZ304450B6 (cs) 2014-05-14
IL151236A (en) 2009-02-11
HU229479B1 (en) 2014-01-28
ES2330552T3 (es) 2009-12-11
CO5271661A1 (es) 2003-04-30
CN1179952C (zh) 2004-12-15
PT1263740E (pt) 2006-11-30
EP1686119A1 (de) 2006-08-02
SK11772002A3 (sk) 2003-02-04
US20100144765A1 (en) 2010-06-10
HUP0204410A3 (en) 2003-07-28
US7652019B2 (en) 2010-01-26
TW550259B (en) 2003-09-01
ES2267714T3 (es) 2007-03-16
US9266841B2 (en) 2016-02-23
MXPA02008062A (es) 2002-11-29
CN1418199A (zh) 2003-05-14
CA2400554A1 (en) 2001-08-23
US7470694B2 (en) 2008-12-30
EP1686119B1 (de) 2009-07-29
DK1686119T3 (da) 2009-11-09
BG66014B1 (bg) 2010-10-29
US20070123549A1 (en) 2007-05-31
US8871775B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
ATE333446T1 (de) Pyrimidin-4-onderivat als ldl-pla2 inhibitor
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
EE200300273A (et) Asendatud imidasopüridiinid
DE60134094D1 (de) C7-taxanester als antitumormittel
DE50107316D1 (de) Neue substituierte imidazotriazinone als pde ii-inhibitoren
DE50013473D1 (de) Pyrrolderivate als phosphodiesterase vii-hemmer
DE60118569D1 (de) 4-phenylpyridin-derivate als neurokinin-1-rezeptor-antagonisten
DE50001663D1 (de) Imidazopyridinderivate als phosphodiesterase vii-hemmer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
ATE300945T1 (de) Isoxazolderivate als phosphodiesterase vii-hemmer
DK1322592T4 (da) Substituerede 1-aminobutan-3-ol-derivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
NO20022983D0 (no) Aminometyl-fenyl-cykloheksanonderivater
ATE367379T1 (de) Quinolin-derivate als antientzündungsmittel
DK1322590T3 (da) Substituerede 5-amino-1-penten-3-ol-derivater
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263740

Country of ref document: EP